News from innovent biologics, inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Sep 17, 2021, 20:00 ET Innovent Releases Interim Analysis Results of Sintilimab plus Chemotherapy for the First-Line Treatment of Esophageal Squamous Cell Carcinoma in the Phase 3 ORIENT-15 Study at ESMO Congress 2021

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high...

Sep 17, 2021, 20:00 ET Innovent Releases Interim Analysis Results of Sintilimab in Combination with Chemotherapy for the First-Line Treatment of Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma in the Phase 3 ORIENT-16 Study at ESMO Congress 2021

Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes...

Aug 26, 2021, 20:00 ET Innovent and Bolt Biotherapeutics Announce Collaboration to Develop Three New Oncology Boltbody™ ISAC Programs

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high...

Jul 14, 2021, 11:30 ET Innovent and Ascentage Pharma Reach Multifaceted Strategic Agreement including Joint Commercialization of Olverembatinib in China, Joint Clinical Development on Multiple Products, and Equity Investment

Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes...

Jul 11, 2021, 20:00 ET Innovent Announces the First Patient Dosed in the Phase 1 Study of IBI323 (Anti-LAG-3/PD-L1 Bispecific Antibody) in Patients with Advanced Malignant Tumors

Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes...

Jun 06, 2021, 20:00 ET Innovent and AnHeart Release Preliminary Results from the Phase II TRUST Trial of Taletrectinib in ROS1 Fusion Positive NSCLC at the ASCO 2021 Annual Meeting

Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes...

Jun 06, 2021, 20:00 ET Innovent Releases the Phase Ia/Ib Dose-Escalation Trial Results of IBI110 (anti-LAG-3) in Patients with Advanced Solid Tumors at ASCO Annual Meeting 2021

Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes...

Jun 06, 2021, 20:00 ET Innovent and HUTCHMED Release Phase 1b preliminary Results of TYVYT (Sintilimab Injection) plus Fruquintinib as a Third Line Treatment for Advanced Colorectal Cancer at ASCO Annual Meeting 2021

Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes...

Jun 06, 2021, 20:00 ET Innovent Releases Phase 1 Results of Pemigatinib in Chinese Patients with Advanced Solid Tumors at ASCO Annual Meeting 2021

Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes...

Jun 02, 2021, 20:00 ET Clinical Trial Results of the BCMA CAR-T Co-developed by Innovent and IASO Biotherapeutics Commented in American Society of Hematology's Medical Journal "Blood"

Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes...

May 24, 2021, 20:00 ET Innovent Announces First Patient Dosed in China in the Global Phase 3 Clinical Trial of Pemigatinib as the First-line Treatment of Unresectable or Metastatic Cholangiocarcinoma

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high...

May 18, 2021, 00:09 ET U.S. FDA Accepts Regulatory Submission for Sintilimab in Combination with Pemetrexed and Platinum Chemotherapy for the First-Line Treatment of People with Nonsquamous Non-Small Cell Lung Cancer

Innovent Biologics, Inc. (HKEX: 01801) and Eli Lilly and Company (NYSE: LLY) today jointly announced that the U.S. Food and Drug Administration (FDA) ...

Feb 28, 2021, 19:00 ET Innovent Announces First Patient Outside China Dosed in the Phase 1 Clinical Trial of Anti-CD47/PD-L1 Bispecific Antibody

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high...

Feb 22, 2021, 20:22 ET The BCMA CAR-T Co-developed by Innovent and IASO Was Granted Breakthrough Therapy Designation by the NMPA for the Treatment of Relapsed/Refractory Multiple Myeloma

Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes...

Feb 08, 2021, 19:00 ET Innovent Announces First Patient Dosed in Phase III Pivotal Trial of IBI310 (CTLA-4) Combined with TYVYT® (sintilimab injection) for the Treatment of First-line Advanced Hepatocellular Carcinoma

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high...

Jan 18, 2021, 19:00 ET Innovent Announces an Out-license Agreement with PT Etana Biotechnologies Indonesia to Launch BYVASDA® (Bevacizumab Biosimilar) in Indonesia

Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes...

Jan 12, 2021, 19:00 ET Innovent Announces NMPA Acceptance of a Supplemental New Drug Application for TYVYT® (sintilimab injection) in Combination with BYVASDA® (bevacizumab injection) as First-Line Therapy in Hepatocellular Carcinoma (HCC)

Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high...

Dec 27, 2020, 19:00 ET Innovent Announces the NMPA Granted New Indication Approval for BYVASDA® (Bevacizumab Biosimilar) for the Treatment of Adult Recurrent Glioblastoma

Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high...

Nov 22, 2020, 19:00 ET Innovent Releases Phase 3 Results of TYVYT® (Sintilimab Injection) in Combination with BYVASDA® (Bevacizumab Biosimilar Injection) as First-Line Treatment in Patients with Advanced Hepatocellular Carcinoma (HCC) at ESMO ASIA Virtual Congress 2020

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes...

Nov 15, 2020, 19:00 ET Innovent Announces the Results of the Phase I Clinical Trial of IBI302, a First-in-class Ophthalmic Recombinant Human Anti-VEGF and Anti-Complement Bi-specific Fusion Protein for Neovascular Age-Related Macular Degeneration at 2020 American Academy of Ophthalmology

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes...

Nov 10, 2020, 19:00 ET Innovent Releases Phase 1a Results of CD47 Monoclonal Antibody (Letaplimab) in Monotherapy for Advanced Malignancies at SITC 2020

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes...

Nov 10, 2020, 19:00 ET Innovation Drives Excellence, Innovent Successfully Held 2020 Virtual R&D Day

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high...

Nov 04, 2020, 19:00 ET Innovent and Lilly Jointly Announce Results of Seven Clinical Studies of TYVYT® (sintilimab injection) to Be Presented at the ESMO ASIA Congress 2020

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high...

Oct 14, 2020, 20:00 ET Innovent Announces the Appointment of Dr. Yong Jun Liu as the President of the Group

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes...

Oct 09, 2020, 07:10 ET Innovent and Lilly Jointly Announce the NMPA Granted Marketing Approval for HALPRYZA® (Rituximab Injection) in China

Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high...